12 November 2021 - The Public Summary Documents (first time rejections and deferrals) from the July 2021 PBAC meeting are now ...
9 November 2021 - Public comment period now open until 8 December 2021; requests to make oral comment during public ...
5 November 2021 - The Outcome Statement from the October 2021 Drug Utilisation SubCommittee meeting is now available. ...
4 November 2021 - Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic ...
20 October 2021 - Independent appraisal committee found the evidence is adequate to demonstrate that eculizumab and efgartigimod both provide a ...
16 September 2021 - Public comment period now open until 14 October 2021; requests to make oral comment during public ...
10 September 2021 - While eculizumab and efgartigimod each provide important health benefits, both would need to be priced more than ...
10 September 2021 - The Public Summary Documents (first time decisions not to recommend, deferrals and other matters) from the May ...
27 August 2021 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the May 2021 PBAC ...
19 August 2021 - With strong public interest in adverse event reports relating to COVID-19 vaccinations, and improvements in our ...
18 August 2021 - Public comment period now open until 15 September 2021; requests to make oral comment during public meeting ...
22 July 2021 - Public comment period now open until 18 August 2021; requests to make oral comment during public meeting ...
16 July 2021 - The Public Summary Documents (first time rejections and deferrals) from the March 2021 PBAC meeting are now ...
9 July 2021 - Evidence demonstrates the JAK inhibitors abrocitinib and upadacitinib are effective treatments for atopic dermatitis, but safety concerns ...
8 July 2021 - Seven additional cases of blood clots with low blood platelets have been assessed as thrombosis with thrombocytopenia ...